UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15 (d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
EXPLANATORY NOTE
As previously disclosed, on November 18, 2025, Axalta Coating Systems Ltd. (“Axalta” or the “Company”) entered into a Merger Agreement (as amended by Amendment No. 1 to Merger Agreement, dated May 27, 2026, and Amendment No. 2 to Merger Agreement, dated July 23, 2026, the “Merger Agreement”) with Akzo Nobel N.V. (“AkzoNobel”), pursuant to which, on the terms and subject to the conditions set forth therein, Axalta and AkzoNobel have agreed to combine their respective businesses in a merger of equals (the “Merger”), with AkzoNobel (upon completion of the Merger, “MergeCo”) serving as the combined company’s listed parent.
On November 17, 2026, AkzoNobel announced the commencement of a private offering of notes (the “Notes”; and the offering of such Notes, the “Notes Offering”) by Akzo Nobel, Inc., a subsidiary of AkzoNobel (the “Notes Issuer”), the proceeds of which may be used in connection with the Merger, as described below. AkzoNobel’s offering memorandum for the Notes Offering incorporates by reference unaudited pro forma condensed combined financial information giving effect to the Merger and the related transactions, consisting of (i) the unaudited pro forma condensed combined balance sheet of MergeCo as of September 30, 2026, giving effect to the Merger and the related transactions as if they had been consummated on September 30, 2026, and the unaudited pro forma condensed combined statement of income of MergeCo for the nine months ended September 30, 2026, giving effect to the Merger and the related transactions as if they had been consummated on January 1, 2025, in each case together with the notes thereto (the “Q3 2026 Pro Forma Financial Information”), and (ii) the unaudited pro forma condensed combined statement of income of MergeCo for the year ended December 31, 2025, giving effect to the Merger and the related transactions as if they had been consummated on January 1, 2025 (the “2025 Pro Forma Financial Information”). AkzoNobel has furnished the Q3 2026 Pro Forma Financial Information to the SEC on a Report on Form 6-K on November 17, 2026 (the “AkzoNobel 6-K”). Because the Q3 2026 Pro Forma Financial Information includes financial information derived from Axalta’s historical financial statements, Axalta is also furnishing the Q3 2026 Pro Forma Financial Information in this Current Report on Form 8-K (this “Current Report”) so that it is made available to Axalta’s investors at the same time it is made available to prospective investors in the Notes Offering. Axalta is not furnishing the 2025 Pro Forma Financial Information, or any other pro forma or historical financial information for the year ended December 31, 2025, in this Current Report. Neither Axalta nor any of its subsidiaries (the “Axalta Group”) is the Notes Issuer, a guarantor or an offeror of the Notes (as defined below) and none of them is offering or selling any securities in the Notes Offering.
The Q3 2026 Pro Forma Financial Information was prepared by AkzoNobel in accordance with Article 11 of Regulation S-X, on the basis of AkzoNobel’s accounting policies under International Financial Reporting Standards as issued by the International Accounting Standards Board and reflects certain reclassifications of, and adjustments to, Axalta’s historical financial information prepared in accordance with U.S. generally accepted accounting principles, and is presented for informational purposes only. It does not purport to represent the actual results of operations or financial position that AkzoNobel and Axalta would have achieved had the companies been combined during the periods or as of the dates presented, and is not intended to project the future results of operations or financial position that MergeCo may achieve.
Completion of the Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, including, among others, receipt of required regulatory clearances, the authorization for listing on the New York Stock Exchange of the AkzoNobel ordinary shares issuable in the Merger and the declaration and payment of a pre-closing distribution to AkzoNobel’s shareholders. No assurance can be given that the Merger will be completed on the timeline currently contemplated or at all.
| Item 7.01. | Regulation FD Disclosure. |
Notes Offering
On November 17, 2026, AkzoNobel announced the commencement of the Notes Offering by the Notes Issuer. The Notes are being offered only to persons who are either reasonably believed to be “qualified institutional buyers” under Rule 144A or who are non-”U.S. persons” under Regulation S as defined under applicable securities laws. The Notes Offering is being conducted solely by the Notes Issuer. No member of the Axalta Group is the Notes Issuer, a guarantor or an offeror of the Notes.
As described in AkzoNobel’s announcement, the net proceeds from the issuance of the Notes are intended to be used for general corporate purposes and may also be used to refinance, from time to time, in whole or in part, (i) the term loans due December 20, 2029 issued and outstanding pursuant to the credit agreement, dated February 1, 2013, by and among Axalta Coating Systems Dutch Holding B.V., Axalta Coating Systems U.S. Holdings, Inc., Axalta Coating Systems U.S., Inc., Axalta, as borrowers, the lenders from time to time party thereto and Barclays Bank PLC, as administrative agent and collateral agent, as amended from time to time, (ii) Axalta’s outstanding $500 million senior notes due 2027, (iii) Axalta’s outstanding $700 million senior notes due 2029 and/or (iv) Axalta’s outstanding $500 million senior notes due 2031, in each case following the completion of the Merger.
This Current Report does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any other securities of Axalta, AkzoNobel or any of their respective subsidiaries, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Financial Information
AkzoNobel has incorporated the Q3 2026 Pro Forma Financial Information by reference into its offering memorandum for the Notes Offering, including by reference to the AkzoNobel 6-K, and has separately incorporated the 2025 Pro Forma Financial Information by reference to its registration statement on Form F-4. The Q3 2026 Pro Forma Financial Information gives effect to the Merger and the related transactions and is an update, to reflect Axalta’s and AkzoNobel’s reported results as of and for the period ended September 30, 2026, of the unaudited pro forma condensed combined financial information included in the registration statement on Form F-4 filed by AkzoNobel with the Securities and Exchange Commission (the “SEC”) in connection with the Merger. The Q3 2026 Pro Forma Financial Information as of and for the nine months ended September 30, 2026 has been prepared in accordance with Article 11 of Regulation S-X, except for the 2025 annual period. The Q3 2026 Pro Forma Financial Information does not give effect to the Notes Offering.
2
Pro Forma Financial Information
The Q3 2026 Pro Forma Financial Information, together with the notes thereto, is furnished with this Current Report as Exhibit 99.1 and incorporated herein by reference. The 2025 Pro Forma Financial Information is not furnished with, and is not incorporated by reference into, this Current Report.
The information contained in Item 7.01 of this Current Report and in Exhibit 99.1 hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Cautionary Statement Concerning Forward-Looking Statements
This communication contains forward-looking statements as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements about management’s expectations of AkzoNobel’s and Axalta’s future operating and financial performance, product development, market position, and business strategy. Such forward-looking statements can sometimes be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “potential,” “seeks,” “aims,” “projects,” “predicts,” “is optimistic,” “intends,” “plans,” “estimates,” “targets,” “anticipates,” “continues” or other comparable terms or negatives of these terms, but not all forward-looking statements include such identifying words. You are cautioned not to rely on these forward-looking statements. Forward-looking statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. We can give no assurance that such plans, estimates or expectations will be achieved and therefore, actual results may differ materially from any plans, estimates or expectations in such forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include: a condition to the closing of the proposed transaction may not be satisfied; the occurrence of any event that can give rise to termination of the proposed transaction; a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AkzoNobel and Axalta are unable to achieve the synergies and value creation contemplated by the proposed transaction; AkzoNobel and Axalta are unable to promptly and effectively integrate their businesses; management’s time and attention is diverted on transaction related issues; the possibility that competing offers or acquisition proposals may be made; disruption from the proposed transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of AkzoNobel or Axalta decline following the proposed transaction; legal proceedings are instituted against AkzoNobel or Axalta,
3
including resulting expense or delay; AkzoNobel or Axalta is unable to retain or hire key personnel; the communication or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of AkzoNobel or Axalta or on AkzoNobel’s or Axalta’s operating results; evolving legal, regulatory and tax regimes; changes in economic, financial, political and regulatory conditions, in the Netherlands, the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics (e.g., the coronavirus (COVID-19) pandemic), geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade and policy changes associated with the current or subsequent United States or Netherlands administration; the ability of AkzoNobel or Axalta to successfully recover from a disaster or other business continuity problem due to a hurricane, flood, earthquake, terrorist attack, war, pandemic, security breach, cyber-attack, power loss, telecommunications failure or other natural or man-made event, including the ability to function remotely during long-term disruptions; the impact of public health crises, such as pandemics and epidemics and any related company or governmental policies and actions to protect the health and safety of individuals or governmental policies or actions to maintain the functioning of national or global economies and markets, including any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down or similar actions and policies; actions by third parties, including government agencies; the risk that disruptions from the proposed transaction will harm AkzoNobel’s or Axalta’s business, including current plans and operations and/or divert management’s attention from AkzoNobel’s or Axalta’s ongoing business operations; certain restrictions during the pendency of the acquisition that may impact AkzoNobel’s or Axalta’s ability to pursue certain business opportunities or strategic transactions; AkzoNobel’s or Axalta’s ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the risks and uncertainties discussed in AkzoNobel’s latest annual report as filed with the AFM, the Dutch trade register and on its website at https://www.akzonobel.com/en/investors/results-center; and the risks and uncertainties discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in Axalta’s reports filed with the SEC. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the proxy statement/prospectus. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Except as required by law, neither AkzoNobel nor Axalta assumes any obligation to update or revise the information contained herein, which speaks only as of the date hereof.
Additional Information and Where to Find It
In connection with the proposed transaction between AkzoNobel and Axalta, AkzoNobel filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 on May 27, 2026, as amended on June 18, 2026, which included a proxy statement of Axalta that also constitutes a prospectus with respect to the shares to be offered by AkzoNobel in the proposed transaction. The registration statement was declared effective by the SEC on June 23, 2026.
4
In connection with the proposed transaction, on June 24, 2026, Axalta filed with the SEC a definitive proxy statement and, on or about June 24, 2026, Axalta commenced mailing the definitive proxy statement to its holders of record as of June 11, 2026. On August 5, 2026, shareholders at the Extraordinary General Meeting of AkzoNobel and Special General Meeting of Axalta, respectively, voted in favor of all resolutions related to the proposed transaction. Each of AkzoNobel and Axalta will also file other relevant documents in connection with the proposed transaction. This communication is not a substitute for any registration statement, proxy statement/prospectus or other documents AkzoNobel and/or Axalta may file with the SEC or any other competent regulator in connection with the proposed transaction. This communication does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. BEFORE MAKING ANY INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS OF AKZONOBEL AND AXALTA ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS, AS APPLICABLE, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT AKZONOBEL, AXALTA, THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement and proxy statement/prospectus and other relevant documents filed by AkzoNobel and Axalta with the SEC are available free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC from Axalta’s investor relations webpage at https://ir.axalta.com/sec-filings/all-sec-filings or from AkzoNobel’s investor relations webpage at https://www.akzonobel.com/en/investors/all-sec-filings.
The contents of this communication should not be construed as financial, legal, business, investment, tax or other professional advice. Each recipient should consult with its own professional advisors for any such matter and advice.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit |
Description | |
| 99.1 | Unaudited Pro Forma Condensed Combined Financial Information of Akzo Nobel N.V. relating to Akzo Nobel N.V. and Axalta Coating Systems Ltd. Merger of Equals | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the iXBRL document) | |
5
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXALTA COATING SYSTEMS LTD. | ||||||
| Date: November 17, 2026 | By: | /s/ Alex Tablin-Wolf | ||||
| Name: | Alex Tablin-Wolf | |||||
| Title: | Senior Vice President, General Counsel and Corporate Secretary | |||||
6